Overview

LGX818 for Patients With BRAFV600 Mutated Tumors

Status:
Terminated
Trial end date:
2015-10-13
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
Phase:
Phase 2
Details
Lead Sponsor:
Array BioPharma
Pfizer